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Objectives This study sought to investigate the evolving pattern over time of on-clopidogrel platelet reactivity (PR) and its
relationship with genotype and clinical outcomes after percutaneous coronary intervention.
Background Whether on-clopidogrel PR and role of genotype differ over time is unknown.
Methods On-clopidogrel PR before percutaneous coronary intervention, and 1 and 6 months thereafter via VerifyNow
P2Y12 (Accumetrics Inc., San Diego, California), CYP2C19*2, *17, CYP3A5*3, and ABCB1 polymorphisms were
evaluated in 300 patients. Death, stroke, myocardial infarction, and bleedings were assessed up to 1 year.
Results On-clopidogrel PR varied significantly over time, being higher at baseline than at 1 and 6 months after. From
baseline to 1 month, 83 of 300 patients varied their response status. This was mainly due to baseline poor re-
sponders becoming full responders (75 of 83). Genotype justifies roughly 18% of this trend. CYP2C19*2 and
*17 influence on PR was consistent over time, whereas that of ABCB1 appeared of greater impact at baseline.
On-clopidogrel PR at 1 month independently best predicts ischemic and bleeding events. We found a therapeutic
window (86 to 238 P2Y12 reactivity units) with a lower incidence of both ischemic and bleeding complications. A
risk score was created by combining genotype (ABCB1 and CYP2C19*2), baseline PR, and creatinine clearance
to predict 1-month poor responsiveness and 1-year poor prognosis.
Conclusions In patients at steady state for clopidogrel undergoing percutaneous coronary intervention, PR decreases from
baseline to 1 month. Genotype influences 18% of this trend. On-clopidogrel PR at 1 month is the strongest
predictor of adverse outcomes, and this can be predicted by combining genotype to baseline phenotype and clin-
ical variables. (J Am Coll Cardiol 2011;57:2474–83) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.12.047d
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tOral P2Y12 inhibitors are a crucial pharmacologic tool in
odern cardiovascular practice. Response to clopidogrel
aries widely among patients, and those with a high residual
n-clopidogrel platelet reactivity (PR) undergoing percuta-
eous coronary intervention (PCI) are at a greater risk for
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linical, genetic, and cellular factors are involved in the
lopidogrel response variability (6–11). Particularly, gene
olymorphisms of proteins involved in absorption and
etabolism of clopidogrel account for approximately 15% to
0% of the variation and are strongly related to poor
rognosis in patients taking clopidogrel (7–10). These
See page 2484
results have been largely provided by studies with a single
phenotype assessment evaluation before or soon after PCI
(1–11). Therefore, whether clopidogrel response varies
hroughout follow-up and whether the role of gene poly-
orphism differs over time is unknown.
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June 21, 2011:2474–83 On-Treatment Platelet Reactivity Over TimeWe sought: 1) to evaluate whether clopidogrel response
in patients treated with PCI differs through follow-up; and
2) to assess the relationship of on-clopidogrel PR at differ-
ent time points with gene polymorphisms and clinical
outcome.
Methods
Patients. Individuals eligible for enrolment were patients
undergoing PCI for ischemic heart disease in our center
from December 2008 to May 2009 (Fig. 1). Exclusion criteria
were known contraindication to dual antiplatelet therapy,
history of chronic inflammatory disease, steroidal and non-
steroidal anti-inflammatory drugs use, glycoprotein IIb/IIIa
inhibitors administration before coronary artery angiogra-
phy, significant bleeding, and/or major surgery within 4
weeks. Subjects were also excluded if they were admitted
with ST-segment elevation acute coronary syndrome. In-
formed written consent was obtained from all patients, and
the study was approved by the local ethics review board.
Study drugs and protocol. All patients were treated with
aspirin (300 mg as loading dose [LD] at hospital admission,
followed by 100 mg die, independently to previous or not
chronic use). Clopidogrel 600 mg was given as LD at least
12 h before PCI. After intervention, clopidogrel 75 mg/day
was continued for 12 months. Anticoagulant and glyco-
protein IIb/IIIa inhibitors treatment was administered at
the interventionalist’s discretion. Of note, only 11 (3%)
patients received glycoprotein IIb/IIIa inhibitors during
PCI. Blood samples were drawn at baseline (just before PCI
and administration of interventional therapy) and at 1 and 6
months after PCI.
Platelet function testing and clopidogrel poor response
definition. To evaluate on-clopidogrel PR, we used Verify-
Now (Accumetrics Inc., San Diego, California). Specific
assays to test clopidogrel (VerifyNow P2Y12) are available.
The results are expressed in P2Y12 reaction units (PRU).
Clopidogrel poor response was defined as a PRU value
235 (3).
Gene polymorphisms. Genomic deoxyribonucleic acid
was extracted from whole-blood samples by Wizard
Genomic DNA Purification Kit (Promega Corporation,
Madison, Wisconsin). Single nucleotide polymorphism
(rs4244285, rs12248560, rs776746, and rs1045642) were
genotyped by allelic discrimination assay (TaqMan As-
says, Applied Biosystems, Foster City, California) on the
Chromo4 Real-Time PCR System detection (Bio-Rad
Laboratories, Hercules, California) using TaqMan Uni-
versal Master Mix. The amplification protocol was as
follow: 50°C for 2 min, 95°C for 10 min, and 40 cycles at
95°C for 15 s, 60°C for 1 min. The data were analyzed by
Opticon Monitor 3.1 software (Bio-Rad Laboratories).
Endpoints of the study. Our primary analysis compared
the incidence of clopidogrel poor responders at baseline
versus 1 month. Secondary assessments include: 1) inci-
dence of clopidogrel poor responders at 1 month versus 6months; 2) rate of death, myo-
cardial infarction, and stroke; 3)
occurrence of definite and prob-
able stent thrombosis according
to the Academic Research Con-
sortium classification; 4) rate of
bleedings according to TIMI
(Thrombolysis In Myocardial
Infarction) classification and
BleedScore (12). Myocardial in-
farction is defined as the recur-
rence of ischemic symptoms and
an elevation of creatine kinase-
myocardial band 3 upper
imit of normal. We reported all
linical events (ischemic and
leeding) after 1 month and up
o 1 year of follow-up. Patients
ith adverse events during the
rst month were excluded.
ample size and statistical analysis. We hypothesized
hat the number of clopidogrel poor responders would
ecrease by 50% after 1 month. Assuming a percentage of
oor responders of 25% at baseline (1–3,5), at least 275
atients were required (alpha and beta of 0.05). Continuous
ata are presented as mean  SD and were tested for
ormal distribution with the Kolmogorov-Smirnov test.
ormally distributed values were compared by t test and
1-way analysis of variance; otherwise, the Mann-Whitney U
and Kruskal-Wallis tests were used. Platelet function data
obtained with VerifyNow were normally distributed. A
linear mixed model was used to quantify changes of on-
clopidogrel PR over time while integrating the role of
baseline, genetic, and procedural characteristics. Categorical
variables were summarized in terms of number and percent-
ages and were compared by using 2-sided Fisher exact test.
The exact version of McNemar test was used to compare
response status at different time points. Survival curves were
generated by the Kaplan-Meier method, and differences in
survival between subgroups were evaluated using the log-
rank test. We applied univariable and multivariable Cox
proportional hazard regression models to evaluate the rela-
tion between the on-clopidogrel PR and the incidence of
the composite clinical endpoint. In our multivariable model,
we adjusted for a broad range of potential confounders,
including clinical, angiographic, and genetic characteristics.
To reduce the impact of data overfitting, we followed a
stepwise modeling approach by applying a variable selection
using the Akaike information criterion and a bootstrapped
variance estimation of the final model. To compare the
ability to discriminate between patients with and without
events of baseline versus 1-month PR receiver-operator
characteristic (ROC) curve analysis is performed. To obtain
a model for the prediction of 1-month poor responsiveness
status, the classification and regression tree method, an
Abbreviations
and Acronyms
CI  confidence interval
HR  hazard ratio
LD  loading dose
NSTEACS  non–ST-
segment elevation acute
coronary syndrome
OR  odds ratio
PCI  percutaneous
coronary intervention
PR  platelet reactivity
PRU  P2Y12 reaction unit
ROC  receiver-operator
characteristic
TIMI  Thrombolysis In
Myocardial Infarctionempirical, statistical technique based on recursive partition-
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tree algorithm was used to analyze potential baseline char-
acteristics of interest and to build up a decision tree
composed of progressive binary splits that were able to
predict 1-month poor response. Finally, the predictive value
of this model was then assessed by determination of 1-year
composite endpoint odds ratios (ORs) and 95% confidence
intervals (CIs) between risk groups. A 2-sided value of p 
0.05 was considered significant. All analyses were performed
with Statistica 8 (Statsoft Inc., Tulsa, Oklahoma), MedCalc
11.2.1 (MedCalc Software, Mariakerke, Belgium), and
R-language (R Foundation, Vienna, Austria).
Results
Study population and genotype. Our study population
includes 300 patients (Fig. 1). No differences were observed
in baseline characteristics between various groups (Table 1).
Genotype frequencies were reported in Table 1. CYP2C19*2
and *17 were in linkage disequilibrium.
On-clopidogrel PR and clopidogrel poor responders.
According to our pre-specified definition, 107 (36%), 40
(13%), and 38 (13%) patients are clopidogrel poor respond-
Figure 1 Study Flow Chart
The flow chart shows the progression of the study from patient enrollment to 1-yea
GPI  glycoprotein inhibitor; LD  loading dose; PCI  percutaneous coronary inte
tion acute coronary syndrome.ers at baseline, 1 month, and 6 months, respectively(p  0.01 comparing baseline vs. 1 month and baseline vs.
6 months). As shown in Figure 2, from baseline to 1 month,
83 of 300 patients changed their responsiveness status (27%,
95% CI: 23% to 33%). Fifty-five of these were admitted for
non–ST-segment elevation acute coronary syndrome
(NSTEACS), whereas 28 were admitted for stable disease
(p  0.2). This is due principally to poor responders at
baseline becoming full responders after 1 month (75 of 83,
90%, 95% CI: 82% to 96%). On the contrary, the variations
observed between 1 and 6 months were minimal, being
limited to only 2 patients (0.7%, 95% CI: 0.1% to 2%).
On-clopidogrel PR, assessed as a continuous variable, was
higher at baseline (190  97) than at 1 (147  85, p 
0.01) and 6 months (146  85, p  0.01), whereas no
significant change was observed between 1 and 6 months
(p  0.9). Although this PR decrease from baseline to 1
month pattern was more pronounced in patients admitted
for NSTEACS (209  96 vs. 159  87 vs. 156  89, p 
0.01), it was also present and significant in patients with
stable disease (161 91 vs. 128 78 vs. 130 77, p 0.01).
Clinical and genetic determinants of on-clopidogrel PR.
Both clinical and genetic factors displayed a significant
influence on-clopidogrel PR. Age, diabetes, creatinine
w-up. Cath-Lab  catheterization laboratory; DAT  dual antiplatelet therapy;
on; PRU  P2Y12 reactivity unit; Pts  patients; STEACS  ST-segment eleva-r follo
rventiclearance, and admission for NSTEACS emerged as inde-
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Age, diabetes, and creatinine clearance had a homogenous
impact over time, whereas admission for NSTEACS
showed a higher influence at baseline (15%) as compared
with 1 month (10%, p  0.07) and 6 months (7%, p 
0.02). Regarding gene polymorphisms, CYP2C19*2,
CYP2C19*17, and ABCB1 justified altogether 18% of PR
variation (6.6%, 5.2%, and 6.7%, respectively). Interestingly,
the CYP2C19*2 and *17 influence appeared constant over
ime, whereas that of ABCB1 was higher at baseline (9%)
and thereafter decreased gradually (6% at 1 month, p 
0.09; 5% at 6 months, p  0.04) (Table 2).
Clinical outcomes. ISCHEMIC ADVERSE EVENTS. The
composite ischemic endpoint occurred in 21 (7%) patients
(6 deaths, 13 reinfarctions, 2 strokes) (Table 3). Four (1.3%)
stent thromboses were observed (Table 3). At univariate
analysis, multivessel PCI, admission for NSTEACS, left
ventricular ejection fraction, ABCB1 T and CYP2C19*2 A
lleles and on-clopidogrel PR (evaluated both at baseline
nd after 1 month) were associated to adverse events. After
ultivariable analysis, only admission for NSTEACS (haz-
rd ratio [HR]: 3.5, 95% CI: 1.2 to 9.6, p  0.04) and
n-clopidogrel PR remained independent outcome predic-
ors. On-clopidogrel PR was a stronger predictor when
Characteristics of the Study PopulationTable 1 Characteristics of the Study Population
All
(n  300)
ABCB1, C3435T
CC
(n  69)
T carriers
(n  231)*
Age, yrs 66 13 65 9 66 14
Male 231 (77) 56 (81) 175 (76)
BMI, kg/m2 27 4 27 3 27 4
Diabetes 71 (24) 16 (22) 55 (24)
Hypertension 215 (72) 46 (66) 169 (73)
Hyperlipidemia 153 (51) 33 (48) 120 (51)
Current cigarette use 71 (24) 19 (27) 52 (23)
Prior MI 81 (27) 17 (27) 64 (28)
Prior PCI 47 (16) 9 (13) 38 (16)
Prior CABG 34 (11) 7 (10) 27 (12)
Admission for NSTEACS 184 (61) 39 (56) 145 (63)
Angiographic/laboratory data
Multivessel 186 (62) 45 (65) 141 (61)
Multivessel PCI 109 (36) 27 (39) 82 (35)
Drug-eluting stent 214 (71) 49 (71) 165 (71)
LVEF, % 51 11 52 9 51 11
Creatinine clearance, ml/min 82 52 90 63 80 42
Medical therapy
Time: clopidogrel to PCI, h 22 8 22 8 21 10
Proton pump inhibitor 158 (53) 34 (49) 124 (54)
Aspirin at 6 months 298 (99) 68 (99) 230 (99)
Clopidogrel at 6 months 290 (97) 67 (97) 228 (99)
Aspirin at 1 year 285 (95) 66 (96) 219 (95)
Clopidogrel at 1 year 263 (88) 59 (86) 204 (88)
Values are mean  SD or n (%). There were *74 (25%) ABCB1 TT homozygotes; †5 (2%) CYP2C19
BMI  body mass index; CABG  coronary artery bypass graft; LVEF  left ventricular ejection
PCI  percutaneous coronary intervention.valuated at 1 month (HR: 1.02, 95% CI: 1.012 to 1.026, v 0.01, as continuous variable; HR: 28.5, 95% CI: 8 to
104, p  0.01, as categorical variable according to the
established cutoff) as compared with baseline assessment
(HR: 1.01, 95% CI: 1.002 to 1.029, p 0.04; HR: 3.1, 95%
CI: 1.3 to 7.3, p  0.02, respectively). To further display
our finding graphically, survival curves were constructed that
showed that poor responders at 1 month had suboptimal
outcomes, whereas poor responders at baseline who subse-
quently became full responders at 1 month had an excellent
prognosis with a remarkably low event rate (Fig. 3). Finally,
at ROC analysis, the ability of on-clopidogrel PR to
discriminate outcomes was significantly better when as-
sessed at 1 month versus that recorded at baseline (differ-
ences between areas: 0.21, 95% CI: 0.05 to 0.33, p  0.01)
(Fig. 4).
BLEEDING ADVERSE EVENTS. We observed 19 (6.3%)
TIMI bleeding events, 4 (1.3%) of which were major.
Regarding BleedScore, 5 alarming, 21 internal, and 30
superficial bleedings occurred. At univariate analysis, age,
creatinine clearance, CYP2C19*17, and on-clopidogrel PR
(both at baseline and at 1 month) predicted composite
bleeding endpoints. After multivariable analysis, age (HR:
1.03, 95% CI: 1.02 to 1.04, p  0.04, as continuous
1A, CYP2C19*2 A6986G, CYP3A5*3 C806T, CYP2C19*17
19)
A Carriers
(n  81)†
GG
(n  263)
A Carriers
(n  37)‡
CC
(n  198)
T Carriers
(n  102)§
14 68 9 66 12 66 18 66 13 66 13
5) 66 (81) 205 (78) 26 (70) 148 (75) 83 (81)
4 28 4 27 4 27 5 27 4 28 4
4) 18 (22) 63 (24) 8 (22) 46 (23) 25 (24)
3) 56 (69) 187 (71) 28 (76) 145 (73) 70 (69)
2) 39 (48) 134 (51) 19 (51) 103 (52) 50 (49)
5) 17 (21) 65 (24) 6 (16) 51 (25) 20 (20)
5) 26 (32) 71 (27) 10 (27) 52 (26) 29 (28)
5) 14 (17) 40 (15) 7 (19) 29 (15) 18 (18)
3) 6 (8) 30 (11) 4 (11) 19 (10) 15 (14)
2) 48 (59) 160 (61) 24 (65) 123 (62) 61 (60)
1) 52 (64) 162 (62) 23 (65) 127 (64) 59 (58)
7) 27 (33) 95 (36) 14 (38) 70 (35) 39 (38)
5) 50 (62) 186 (71) 28 (76) 139 (70) 75 (73)
10 50 12 51 11 51 11 50 11 51 10
59 78 40 83 55 79 42 84 61 79 41
10 22 9 22 9 22 8 21 10 22 8
2) 46 (56) 138 (52) 20 (54) 101 (51) 57 (55)
9) 81 (99) 261 (99) 37 (100) 197 (99) 101 (99)
7) 77 (95) 256 (97) 36 (97) 192 (97) 98 (96)
5) 77 (95) 250 (95) 35 (94) 188 (95) 97 (95)
8) 71 (87) 230 (87) 33 (89) 173 (87) 90 (88)
homozygotes; ‡2 (1%) CYP3A5*3 AA homozygotes; and §17 (6%) CYP2C19*17 TT homozygotes.
; MI  myocardial infarction; NSTEACS  non–ST-segment elevation acute coronary syndrome;G68
GG
(n  2
65
165 (7
27
53 (2
159 (7
114 (5
54 (2
55 (2
33 (1
28 (1
136 (6
134 (6
82 (3
164 (7
52
84
21
112 (5
218 (9
213 (9
208 (9
192 (8
*2 AAariable), CYP2C19*17 genotype (HR: 2.3, 95% CI: 1.03 to
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(HR: 0.94, 95% CI: 0.93 to 0.95, p  0.04, as continuous
variable) emerged as independent predictors. As for isch-
emic endpoint, ROC analysis confirmed that 1-month
on-clopidogrel PR values better discriminate bleeding com-
Figure 2 Responsiveness Status at Baseline and After 1 Month
Bar graph shows the responsiveness status at baseline and after 1 month. p  0
line versus 6-month response status; p  0.9 comparing 1-month versus 6-month
responders (FRs) are blue.
Genotype and On-Clopidogrel PR ValuesTable 2 Genotype and On-Clopidogrel PR Values
Baseline
n (%) PRU p Value n (
ABCB1, C3435T
CC 69 (23) 159 97 0.03 69
CT 157 (52) 187 94 157
TT 74 (25) 227 91 74
T carriers 231 (77) 200 95 0.01 231
G681A, CYP2C19*2
GG 219 (73) 181 97 0.01 219
GA 76 (25) 216 92† 76
AA 5 (2) 236 112† 5
A carriers 81 (27) 216 91 0.01 81
A6986G, CYP3A5*3
GG 263 (87) 188 95 0.5 253
GA 35 (12) 205 106 34
AA 2 (1) 226 129 2
A carriers 37 (13) 207 106 0.3 37
C806T, CYP2C19*17
CC 198 (66) 203 92 0.01 198
CT 85 (28) 171 100† 85
TT 17 (6) 139 100† 17
T carriers 102 (34) 165 101 0.01 102PRU data are mean  SD. *Blood sample available in 281 patients. †p  0.05 versus wild type.
PR  platelet reactivity; PRU  P2Y12 reactivity unit.plications (differences between areas: 0.2, 95% CI: 0.1 to
0.3, p  0.01) (Fig. 4). Finally, in Figure 5, we showed
the combined incidence of ischemic and bleeding events
across groups stratified for best cutoff of 1-month on-
clopidogrel PR.
mparing baseline versus 1-month response status; p  0.01 comparing base-
nse status. Patients (Pts) who are poor responders (PRs) are red and full
1 Month 6 Months*
PRU p Value n (%) PRU p Value
125 84 0.01 68 (24) 128 80 0.01
146 82 145 (52) 143 81
170 87 68 (24) 169 95
153 84 0.01 213 (76) 152 87 0.01
133 81 0.01 204 (73) 132 81 0.01
182 88† 73 (26) 180 85†
221 105† 4 (1) 218 95†
185 90 0.01 77 (27) 183 87 0.01
148 83 0.6 246 (87) 148 85 0.6
147 93 33 (12) 143 87
167 209 2 (1) 152 208
139 97 0.5 35 (12) 134 93 0.4
163 83 0.01 185 (66) 163 81 0.01
122 79† 79 (28) 119 83†
88 88† 17 (6) 88 93†
117 81 0.01 96 (34) 113 85 0.01.01 co
respo%)
(23)
(52)
(25)
(77)
(73)
(25)
(2)
(27)
(87)
(12)
(1)
(13)
(66)
(28)
(6)
(34)
istaxis)
ocardia
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As poor response at 1 month was identified as the strongest
predictor of adverse outcomes, we elaborated a score risk,
Incidence of Adverse Events (Ischemic and Bleeding) According GeTable 3 Incidence of Adverse Events (Ischemic and Bleeding)
Ischemic Events
Death ST
Death  MI 
stroke p V
ABCB1, C3435T (n)
CC (69) 0 (0) 0 (0) 1 (1.5)
T carriers (231) 6 (2.5) 4 (1.7) 20 (8.6)
G681A, CYP2C19*2 (n)
GG (219) 4 (1.8) 3 (1.4) 11 (5.0)
A carriers (81) 2 (2.5) 1 (1.2) 10 (12.3)
A6986G, CYP3A5*3 (n)
GG (263) 4 (1.5) 3 (1.1) 17 (6.5)
A carriers (37) 2 (5.4) 1 (2.7) 4 (10.8)
C806T CYP2C19*17 (n)
CC (198) 5 (2.5) 4 (2.0) 16 (8.1)
T carriers (102) 1 (1.0) 0 (0) 5 (4.9)
Baseline response (n)
Full R (193) 3 (1.5) 2 (1.0) 7 (3.6) 
Poor R (107) 3 (2.8) 2 (1.9) 14 (13)
1-month response (n)
Full R (260) 1 (0.4) 1 (0.4) 4 (1.5) 
Poor R (40) 5 (12.5) 3 (7.5) 17 (42.5)
Values are n (%). *The p value is for the composite endpoint. †According to TIMI classification. ‡Th
(1 intracranial, 4 needing transfusion)  internal (5 melena, 5 hematuria, 1 hematemesis, 10 ep
MI  myocardial infarction; R  responder; ST  stent thrombosis; TIMI  Thrombolysis In My
Figure 3 Cumulative Incidence of 1-Year Composite Ischemic E
According to Responsiveness Status at Baseline and
Graph shows the cumulative incidence of 1-year composite ischemic endpoint. Re
month. Solid red line represents poor R at baseline and 1 month. Dotted blue lin
sents full R at baseline and 1 month.combining baseline characteristics, to predict responsiveness
status at 1 month. ABCB1 and CYP2C19*2 gene polymor-
phisms (CC and GG homozygotes vs. T and/or A carriers),
pe and Clopidogrel Responsiveness Statusrding Genotype and Clopidogrel Responsiveness Status
Bleeding Events
Minor 
Major† p Value‡ Superficial§
Internal 
Alarming§ p Value
7 (10.1) 0.3 8 (11.5) 8 (11.6) 0.6
12 (5.2) 22 (9.5) 18 (7.8)
16 (7.3) 0.4 22 (10.1) 20 (9.1) 0.4
3 (3.7) 8 (9.8) 6 (7.4)
16 (6.1) 0.7 26 (9.8) 23 (8.7) 0.6
3 (8.1) 4 (10.8) 3 (8.1)
6 (3) 0.01 18 (9.1) 10 (5) 0.01
13 (12.7) 12 (11.7) 16 (16)
13 (6.7) 0.8 21 (10.8) 18 (9.3) 0.3
6 (5.6) 9 (8.4) 8 (7.5)
18 (7) 0.5 27 (10.4) 25 (9.6) 0.2
1 (2.5) 3 (7.5) 1 (2.5)
e for minormajor bleedings. §According to BleedScore classification. The p value for alarming
bleedings.
l Infarction.
int
Month
ed line represents full responders (R) at baseline who became poor R at 1
sents poor R at baseline who became full R at 1 month. Solid blue line repre-notyAcco
alue*
0.02
0.03
0.3
0.1
0.01
0.01
e p valundpo
at 1
d dash
e repre
p
c
(
(
f
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258 PRU) and creatinine clearance (above vs. below 52
ml/min) were identified as the best 1-month PR predictors
(Fig. 6). Particularly, ABCB1 and CYP2C19*2 wild-type
atients or patients with baseline PRU 258 and creatinine
learance 52 ml/min showed low PRU values at 1 month
only 6 poor responders of 196, 3%, 95% CI: 1% to 6%)
Fig. 6). On the contrary, carriers of at least 1 loss of
unction allele for ABCB1 and/or CYP2C19 plus high
baseline PRU values and/or low creatinine clearance were at
Figure 4 Comparison of ROC Curves for PRU Values at Baselin
(A) Receiver-operator characteristic (ROC) analysis for ischemic composite endpoi
AUC  area under the curve; NPV  negative predictive value; PPV  positive pre
Figure 5 Adverse Events and Levels of
P2Y12 Receptor Inhibition at 1 Month
Patients are stratified into groups of enhanced responders (PRU 85), normal
responders (PRU 86 to 238) and poor responders (PRU 239). BEP  bleed-
ing endpoint; IEP  ischemic endpoint; other abbreviations as in Figure 1.highest risk of 1-month high PR and as such of subsequent
adverse events (Fig. 6).
Discussion
The main findings of this prospective investigation can be
summarized as follows:
1. On-clopidogrel PR showed a significant reduction from
index hospitalization to 1 month. The percentage of
poor responders decreased from 35% (95% CI: 30% to
41%) at baseline to 13% (95% CI: 9% to 18%) at 1
month.
2. Gene polymorphisms justified about 18% of this trend.
CYP2C19*2 and *17 influence was apparently consistent
over time, whereas ABCB1 showed a higher impact at
baseline.
3. We found a “therapeutic window of PRU values” where
both ischemic and bleeding adverse events are mini-
mized. Then, on-clopidogrel PR may be used to predict
both complications, particularly when assessed at 1
month after index procedure.
To the best of our knowledge, only a pilot study involving
33 stable patients has previously evaluated the pattern of
on-clopidogrel PR over time showing no increase in platelet
aggregation or change in the prevalence poor response over
time (13). The sample size of our study was almost 10-fold
greater, and we included both unstable and stable patients.
Contrary to previous findings, we observed a significant
decrease of on-clopidogrel PR from baseline (index hospi-
at 1 Month
ROC analysis for bleeding composite endpoint.
value; PRU  P2Y12 reactivity unit; sen  sensitivity; spec  specificity.e and
nt. (B)
dictivetalization) to 1 month, without further changes up to 6
c
p
c
h
t
a
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patients admitted for NSTEACS, a consistent PR modifi-
cation over time was noted also in stable patients. In our
study, an LD of 600 mg of clopidogrel was systematically
used. One could speculate that a higher LD (e.g., 900 mg)
can induce a better early platelet inhibition, minimizing the
drop from baseline to 1 month. Yet, results from previous
studies are conflicting (14,15) and doses higher than 600 mg
seem not to be associated with an additional significant
suppression of platelet function because of limited absorp-
tion (15). Also the time between LD administration and
platelet function evaluation/PCI in our study (22  8 h)
well reflects the daily clinical practice and it was meant to
allow clopidogrel to reach a steady-state scenario.
In our study, both clinical and genetic factors influenced
on-clopidogrel PR. ABCB1 and CYP2C19*2 and *17 ac-
ounted for approximately 18% of variability in clopidogrel
latelet response. Interestingly, the reduction of on-
lopidogrel PR from baseline to 1 month appeared to be
omogenous across different allele variants. Moreover, for
he first time, we reported that CYP2C19*2 and *17 consis-
tently influenced PR over time, whereas the role of ABCB1
ppeared to be reduced during follow-up. As ABCB1 is
involved in the process of clopidogrel absorption, it is
reasonable to speculate that its role may be relatively more
relevant in the first days after start of the treatment.
Recently, the genetic substudy of the PLATO (Platelet
Inhibition and Patient Outcomes) trial (16) has reported
Figure 6 Risk Score Predicting 1-Month Poor Responsiveness
The score is calculated adding 1 point for the presence of each of the following va
baseline PR 258 PRU, and creatinine clearance (CrCl) 52 ml/min. *As comparthat carriers of allele variants associated with poor clopi-dogrel effect showed a higher ischemic event rate mainly
within the first 30 days after start of treatment. Interest-
ingly, the prognostic impact of clopidogrel loss-of-function
alleles seemed less relevant after 30 days. Our data may help
to explain this finding. We found that carriers of loss-of-
function alleles consistently display higher on-clopidogrel
PR as compared to wild-type patients. Nevertheless, after 1
month, on-clopidogrel PR decreases significantly in wild-
type patients as well as in loss-of-function allele carriers.
Then, although these patients have higher on-clopidogrel
PR, the number of patients with PRU values above the
established cutoffs predicting adverse events is relatively
small and similar to that of wild-type patients. This mech-
anistic observation may thus at least partially explain why
the risk of adverse events as conveyed by loss-of-function
alleles may be highest in the first days after the start of the
treatment with clopidogrel. Alternatively, this may be par-
tially driven by early discontinuation of clopidogrel after 30
days or by a chance finding that merits further investigation.
Similar to previous studies, we found that PR expressed
as a PRU value was an independent predictor of poor
prognosis. At ROC analysis, the PRU cutoff value that best
discriminated ischemic events tended to be slightly inferior
(214 vs. 235 to 240) to previous analyses, but this is
consistent with what we previously observed in the 3T/2R
(Tailoring Treatment With Tirofiban in Patients Showing
Resistance to Aspirin and/or Resistance to Clopidogrel)
trial (5–17), and probably due to a different study population
s
s: ABCB1 T and/or CYP2C*19 A carriage,
h the risk score 1 group. Abbreviations as in Figures 1 and 3.Statu
riable
ed witselection. The new important information emerging from
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1 month. By testing on-clopidogrel PR 1 month after index
procedure, we significantly improved the ability of PR to
discriminate between patients with and without adverse
events via a distinct reduction of “false poor responders.”
Baseline PRU values are influenced by several confounding
factors, particularly acute atherothrombotic events and in-
flammation. All these factors progressively either reduce
their influence or disappear, and then the 1-month evalua-
tion permits us to better discriminate patients with chronic
and persistent high on-clopidogrel PR. Moreover, in the
early phase, clinical presentation, PCI success, and compli-
cations related to procedure or hospitalization might have a
stronger impact on short-term outcome than clopidogrel
poor response would. Contrarily, in the later phase, all these
factors are less important and the “true clopidogrel poor
response” emerges as the strongest determinant of poor
prognosis. This has relevant clinical implications especially
in the context of current ongoing studies trying to identify
a “tailored anti-platelet regimen” based on a single baseline
PR assessment. Patients labeled as “poor responder” at
baseline, who then became full responders after 1 month
showed an excellent clinical outcome in our study, which
was very close to that of patients who were full responders
both at baseline and at 1-month evaluation. Thus, we may
speculate that a more aggressive antiplatelet treatment may
not be needed and may be even potentially harmful. On the
other hand, re-evaluating PRU at 1 month after the index
procedure carries several drawbacks, limiting a rapidly tai-
lored approach, avoiding the early treatment of true poor
responders, and the prevention of acute and subacute
ischemic adverse events. To avoid these limitations, a
stratification based on the combination of genotype and
phenotype variables may be desirable. In our study popula-
tion, and similar to previous studies (9), genotype informa-
tion alone showed lower predictive power as compared with
on-clopidogrel PR values, and it was not sufficient to
discriminate the majority of patients who would be poor
responders at 1 month. On the contrary, by mixing geno-
type and 2 simple baseline characteristics (on-clopidogrel
PR and creatinine clearance), we were able to obtain a new
risk score model that was able to predict the majority of poor
responders after 1 month and with adverse events. Interest-
ingly, of all clinical parameters, creatinine clearance
emerged in our score. Probably, because it includes age, sex,
and, in particular, renal function. Impaired renal function is
frequent in patients who are elderly and diabetic, which are
known factors relating to higher PR. Consistently, recent
studies showed lower clopidogrel-induced antiplatelet ef-
fects and a greater prevalence of on-clopidogrel high PR in
patients with chronic kidney disease (18). The proposed risk
score algorithm should be regarded as the first attempt to
predict high on-clopidogrel PR at 1 month from baseline
variables. Therefore, future larger prospective studies are
clearly in demand to evaluate the clinical utility of this or
similar risk scores.Finally, according to previous studies (8), we found that
both CYP2C19*17 polymorphism and low on-clopidogrel
PR values were associated with bleeding events. As in
Sibbing et al. (19), we too found a therapeutic window
(between 86 and 238 PRU) with a lower incidence of both
ischemic and bleeding complications. Contrarily, we used
VerifyNow assay (vs. Multiplate analyzer, Verum Diagnos-
tica, Munich, Germany), we collected bleeding events
during follow-up (vs. in-hospital), and we found that blood
samples collected at 1 month are better than those collected
at baseline. Nevertheless, our findings are consistent and
support the existence of a threshold phenomenon both for
ischemic and bleeding events.
Study limitations. Our a priori sample size calculation was
aimed to assess the change of PR over time after treatment
with clopidogrel. Therefore, not surprisingly, there was a
small number of ischemic and bleeding events noted
throughout follow-up in our study. Consequently, our data
and, in particular, our score to predict 1-month poor
responsiveness status should be considered exploratory and
new larger studies are needed to confirm them. Moreover,
our study is limited by the use of only 1 test to evaluate
on-clopidogrel PR, the point-of-care assay VerifyNow.
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